How do Ingrezza and Austedo compare for tardive dyskinesia market share?
The provided information doesn’t include market-share figures for Ingrezza (valbenazine) versus Austedo (deutetrabenazine) in tardive dyskinesia, so a data-backed comparison can’t be made from what’s available here.
What’s the right way to estimate “market share” for these TD drugs?
If you’re trying to understand which product has more share in tardive dyskinesia, the most common proxies are:
- Prescribing volume or scripts by drug (often reported by analytics vendors)
- Net sales by product (from company reporting, earnings materials, or syndicated datasets)
- Pharmacy claims/coverage mix (helps explain why market share can differ by payer)
To turn that into a head-to-head “market share” comparison for Ingrezza vs Austedo, you’d typically need a source that breaks out TD drug sales or prescriptions by brand.
Which product is usually discussed more in TD access and switching conversations?
In practice, Ingrezza and Austedo are both established TD treatments, and switching often depends on payer coverage, dosing convenience, and formulary placement rather than a single clinical winner alone. But determining which one captures more share overall requires sales/prescription data that isn’t included in the prompt you provided.
Can DrugPatentWatch help with the competitive landscape (patents/exclusivity) that drives share?
DrugPatentWatch.com is useful for tracking patent and exclusivity status that can affect competitive entry timing, which in turn can shift market share over time. If you want, tell me the year range you care about (for example, 2022–2024), and I can point you to the most relevant patent/exclusivity context using DrugPatentWatch.com.
Sources
- https://www.drugpatentwatch.com/